Tigecycline 50mg powder for solution for infusion vials
Requires a prescription from a doctor or prescriber
Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil.
Safety information for pregnancy and breastfeeding
Pregnancy
Always consult your doctor or midwife before taking any medicine during pregnancy or while breastfeeding. Source: DrugBank (CC BY-NC 4.0).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Tigecycline
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Tigecycline
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Tigecycline
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
7 branded products available
MHRA licensed products
View all licensed products for Tigecycline on the MHRA register
Tygacil 50mg powder for solution for infusion vials
Tigecycline 50mg powder for solution for infusion vials
Tigecycline 50mg powder for solution for infusion vials
Tigecycline 50mg powder for solution for infusion vials
Tigecycline 50mg powder for solution for infusion vials
Tigecycline 50mg powder for solution for infusion vials
Tigecycline 50mg powder for solution for infusion vials
WHO defined daily dose (DDD)
100 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(5)
Antimicrobial prescribing: meropenem with vaborbactam (ES21)
Cellulitis and erysipelas: antimicrobial prescribing (NG141)
Xpert Carba-R to identify people carrying carbapenemase-producing organisms (MIB52)
Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (AMR1)
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 23 · Randomised trials: 2 · 2003–2023
Showing the 50 most relevant studies, sorted by most relevant.
Dafna Yahav, Adi Lador, Mical Paul, et al.
Journal of Antimicrobial Chemotherapy, 2011
- Tigecycline
- Anti-Bacterial Agents
- Bacterial Infections
Theodoros Kelesidis, Drosos E. Karageorgopoulos, Iosif Kelesidis, et al.
Journal of Antimicrobial Chemotherapy, 2008
- Drug Resistance, Multiple, Bacterial
- Tigecycline
- Anti-Bacterial Agents
Yun Cai, Rui Wang, Beibei Liang, et al.
Antimicrobial Agents and Chemotherapy, 2010
- Tigecycline
- Anti-Bacterial Agents
- Communicable Diseases
Paritosh Prasad, Junfeng Sun, Robert L. Danner, et al.
Clinical Infectious Diseases, 2012
- Tigecycline
- Anti-Bacterial Agents
- Minocycline
Efthimia Tasina, Anna‐Bettina Haidich, Stamatia Kokkali, et al.
The Lancet Infectious Diseases, 2011
- Tigecycline
- Anti-Bacterial Agents
- Bacterial Infections
Wentao Ni, Yuliang Han, Jie Liu, et al.
Medicine, 2016
- Tigecycline
- Anti-Bacterial Agents
- Enterobacteriaceae Infections
Julio A. Ramírez, Nathalie Dartois, Hassan Gandjini, et al.
Antimicrobial Agents and Chemotherapy, 2013
- Cilastatin, Imipenem Drug Combination
- Tigecycline
- Anti-Bacterial Agents
Jian Wang, Ya-ping Pan, Jilu Shen, et al.
Annals of Clinical Microbiology and Antimicrobials, 2017
- Tigecycline
- Anti-Bacterial Agents
- Minocycline
Sajad Yaghoubi, Angelina Olegovna Zekiy, Marcela Krůtová, et al.
European Journal of Clinical Microbiology & Infectious Diseases, 2021
- Anti-Bacterial Agents
- Community-Acquired Infections
- Tigecycline
Aref Shariati, Masoud Dadashi, Zahra Chegini, et al.
Antimicrobial Resistance and Infection Control, 2020
- Linezolid
- Tigecycline
- Anti-Bacterial Agents
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
27-43 hours
Mechanism
Tigecycline, a glycylcycline, inhibits protein translation in bacteria by bindin…
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
27-43 hours
Protein binding
71%
Metabolism
10%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 287 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
ATC J01AA20
ATC J01AA12
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Tigecycline
Additional database identifiers
Drugs Product Database (DPD)
19932
ChemSpider
10482314
BindingDB
50247905
ZINC
ZINC000014879972
GenBank Gene Database
X02130
GenBank Protein Database
535073
UniProt Accession
RS9_ECOLI
GenBank Gene Database
V00355
GenBank Protein Database
43010
UniProt Accession
RS12_ECOLI
GenBank Gene Database
X02543
GenBank Protein Database
581217
UniProt Accession
RS13_ECOLI
GenBank Gene Database
X01563
GenBank Protein Database
809690
UniProt Accession
RS14_ECOLI
GenBank Gene Database
X02613
GenBank Protein Database
42826
UniProt Accession
RS19_ECOLI
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72